This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Roche to Evaluate Actemra for Severe COVID-19 Pneumonia
by Zacks Equity Research
Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
Pfizer, Regeneron Give Update on Coronavirus Drug Development
by Kinjel Shah
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Top Stock Reports for UnitedHealth, Sanofi & United Parcel
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Sanofi (SNY) and United Parcel Service (UPS).
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection
by Kinjel Shah
A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.
Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts
by Zacks Equity Research
Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.
J&J Signs Another Collaboration to Develop Coronavirus Vaccine
by Zacks Equity Research
J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.
Inovio (INO) Posts Wider Q4 Loss, Gets COVID-19 Vaccine Grant
by Zacks Equity Research
Inovio's (INO) loss in the fourth quarter falls shy of estimates and revenues too miss the mark. The company is focused on developing INO-4800, its DNA vaccine, against COVID-19.
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Lilly Expects No Drug Supply Shortages Due to Coronavirus
by Zacks Equity Research
Lilly (LLY) does not expect shortage in supply of its medicines as it does not source APIs of any of its marketed drugs from China.
5 Drug Makers to Gain From Coronavirus Outbreak
by Zacks Equity Research
Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.
Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
by Kinjel Shah
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Sanofi Plans Spin-Off of API Unit Into a European Company
by Zacks Equity Research
Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.